At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating Atomoxetine and Placebo for Memory Disorders and Multiple Sclerosis. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMemory Disorders, Multiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedMar 27, 2017
Enrollment StartMar 16, 2017
Primary CompletionJun 11, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.3 years ago
Interventions
Atomoxetinedrug
Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Placebodrug
Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)